OverviewSuggest Edit

Agios Pharmaceuticals is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases.

Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. The Company intends to apply its deep understanding of metabolism, coupled with its ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.

Agios also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The Company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases.

TypePublic
Founded2008
HQCambridge, US
Websiteagios.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Feb 2019)382
Job Openings49
Revenue (FY, 2018)$94.4 M(+120%)
Share Price (Mar 2019)$64.8

Key People/Management at Agios Pharmaceuticals

Jacqualyn Fouse

Jacqualyn Fouse

CEO, Agios Pharmaceuticals
Scott Biller

Scott Biller

Chief Scientific Officer
Chris Bowden

Chris Bowden

Chief Medical Officer
Andrew Hirsch

Andrew Hirsch

Chief Financial Officer and Head of Corporate Development
Steve Hoerter

Steve Hoerter

Chief Commercial Officer
Melissa McLaughlin

Melissa McLaughlin

Chief People Officer
Show more

Agios Pharmaceuticals Office Locations

Agios Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
88 Sidney St
Show all (1)
Report incorrect company information

Agios Pharmaceuticals Financials and Metrics

Agios Pharmaceuticals Revenue

Agios Pharmaceuticals's revenue was reported to be $94.39 m in FY, 2018
USD

Revenue (FY, 2018)

94.4m

Gross profit (FY, 2018)

93.0m

Gross profit margin (FY, 2018), %

98.5%

Net income (FY, 2018)

(346.0m)

EBIT (FY, 2018)

(362.5m)

Market capitalization (18-Mar-2019)

3.8b

Closing stock price (18-Mar-2019)

64.8

Cash (31-Dec-2018)

70.5m
Agios Pharmaceuticals's current market capitalization is $3.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

25.5m65.4m59.1m69.9m43.0m94.4m

Revenue growth, %

156%(10%)18%

Cost of goods sold

1.4m

Gross profit

93.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

6.3m8.4m34.2m13.2m5.5m31.3m7.0m9.0m10.5m11.4m8.8m49.2m15.2m

Cost of goods sold

695.0k

Gross profit

14.5m

Gross profit Margin, %

95%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

71.6m14.0m71.8m160.8m102.7m70.5m

Accounts Receivable

2.3m600.0k5.1m

Inventories

2.5m4.8m8.7m10.3m869.0k

Current Assets

169.7m359.5m337.3m559.9m445.3m613.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

106.0m32.8m108.2m70.0m35.3m72.5m80.0m39.0m234.0m285.5m200.3m138.7m132.7m364.5m210.3m156.5m

Accounts Receivable

2.6m

Inventories

863.0k

Current Assets

198.8m172.4m245.2m247.6m364.1m390.2m371.7m329.5m484.2m600.9m506.9m604.7m528.3m803.0m753.8m695.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(39.4m)(53.5m)(117.7m)(198.5m)(314.7m)(346.0m)

Depreciation and Amortization

1.4m1.4m3.3m5.7m6.4m7.2m

Inventories

(869.0k)

Accounts Payable

30.0k7.6m4.2m3.5m5.3m(5.5m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(11.2m)(12.2m)(18.3m)(26.8m)(5.0m)(36.9m)(77.1m)(23.2m)(79.2m)(142.0m)(66.2m)(149.2m)(226.4m)(90.8m)(159.6m)(254.2m)

Depreciation and Amortization

332.0k1.0m1.2m2.2m1.2m2.6m4.0m1.6m3.2m4.8m1.7m3.5m5.3m

Inventories

(863.0k)

Accounts Payable

720.0k5.4m2.4m12.6m(1.2m)(1.3m)(293.0k)3.8m1.7m(994.0k)4.9m742.0k(4.5m)(6.2m)(5.8m)
USDY, 2018

Revenue/Employee

247.1k

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Agios Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Agios Pharmaceuticals News and Updates

FDA approves Agios Pharmaceuticals leukemia drug

Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator.
Report incorrect company information

Agios Pharmaceuticals Blogs

Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients

– Overall Response Rate of 78%, CR+CRh Rate of 65% and 12-month Survival Rate of 82% – – With Longer Follow Up Data, CR Rate Increased to 57% with Majority of Patients with CR Achieving IDH1 Mutation Clearance – – Mean Neutrophil and Platelet Counts Were Maintained Near or Above CRh Thresholds

Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019

CAMBRIDGE, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Leerink Global Healthcare Conference in New York

Agios at Leerink Global Healthcare Conference

Agios at Leerink Global Healthcare Conference william.meady@… Wed, 02/20/2019 - 10:54 Agios at Leerink Global Healthcare Conference Display "add to calendar" false Event Type Conference Presentation Click here for webcast …

Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy

Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy Content Import Wed, 02/20/2019 - 07:05 Agios Announces FDA Accepta…

Agios Reports Fourth Quarter and Full Year 2018 Financial Results

Agios Reports Fourth Quarter and Full Year 2018 Financial Results Content Import Thu, 02/14/2019 - 07:06 Agios Reports Fourth Quarter and Full Year 2018 Financial Results Feb 14, 2019 This release is a backfill from a News Wire Earnings …

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019 Content Import Thu, 01/31/2019 - 07:03 Agios to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019 Jan 31, 2019 …
Show more

Agios Pharmaceuticals Frequently Asked Questions

  • When was Agios Pharmaceuticals founded?

    Agios Pharmaceuticals was founded in 2008.

  • Who are Agios Pharmaceuticals key executives?

    Agios Pharmaceuticals's key executives are Jacqualyn Fouse, Scott Biller and Chris Bowden.

  • How many employees does Agios Pharmaceuticals have?

    Agios Pharmaceuticals has 382 employees.

  • What is Agios Pharmaceuticals revenue?

    Latest Agios Pharmaceuticals annual revenue is $94.4 m.

  • What is Agios Pharmaceuticals revenue per employee?

    Latest Agios Pharmaceuticals revenue per employee is $247.1 k.

  • Who are Agios Pharmaceuticals competitors?

    Competitors of Agios Pharmaceuticals include Varex Imaging, Vivace Therapeutics and Merrimack Pharmaceuticals.

  • Where is Agios Pharmaceuticals headquarters?

    Agios Pharmaceuticals headquarters is located at 88 Sidney St, Cambridge.

  • Where are Agios Pharmaceuticals offices?

    Agios Pharmaceuticals has an office in Cambridge.

  • How many offices does Agios Pharmaceuticals have?

    Agios Pharmaceuticals has 1 office.